Literature DB >> 9923580

Interaction of citrus juices with pranidipine, a new 1,4-dihydropyridine calcium antagonist, in healthy subjects.

K Hashimoto1, T Shirafuji, H Sekino, O Matsuoka, H Sekino, O Onnagawa, T Okamoto, S Kudo, J Azuma.   

Abstract

OBJECTIVES: The study was conducted to investigate whether oral co-administration with citrus juices significantly affects the pharmacokinetics and/or pharmacodynamics of pranidipine, a new 1,4-dihydropyridine calcium antagonist, in healthy male subjects. Grapefruit juice and orange juice, which were both commercially available, were used in this study.
METHODS: Sixteen healthy male Japanese subjects participated in this study and were divided into two groups for grapefruit juice and orange juice treatment. The study followed an open-labelled crossover design, comparing the effects of a single oral dose of 2 mg pranidipine taken together with 250 ml citrus juice or 250 ml water. Serum pharmacokinetics of pranidipine, adverse reactions, blood pressure, heart rate, 12-lead ECG, haematology, clinical chemistry and urinalysis were measured throughout the study.
RESULTS: For grapefruit juice, mean Cmax and AUC0-24 h were significantly higher than those of water (P=0.0003 and 0.0005, respectively, ANOVA) with the ratios of log transformed values being 1.50 and 1.74, respectively. There were no differences in tmax and t1/2 between the juice and water treatments. A significant increase in heart rate (P=0.0240, ANOVA with repeated measurements) was observed in the juice treatment whereas there were no significant differences in systolic and diastolic blood pressure between the two treatments. For orange juice, a small decrease in mean Cmax was observed compared with water (P=0.0218, ANOVA) with the ratio being 0.86, but there was no significant difference in AUC0-24h between the two treatments. No marked differences were observed in tmax and t1/2. Oral pranidipine administration with orange juice did not affect heart rate, systolic and diastolic blood pressures or other parameters for safety evaluation.
CONCLUSIONS: Oral co-administration with grapefruit juice and pranidipine was associated with increased bioavailability and changed the pharmacodynamics of pranidipine, particularly with regard to heart rate. Orange juice intake with pranidipine did not markedly affect the pharmacokinetics and no clinically significant changes were observed in the pharmacodynamics and safety evaluation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9923580     DOI: 10.1007/s002280050547

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  7 in total

1.  Major determinant factors of the extent of interaction between grapefruit juice and calcium channel antagonists.

Authors:  Ayako Ohnishi; Hisakazu Ohtani; Yasufumi Sawada
Journal:  Br J Clin Pharmacol       Date:  2006-08       Impact factor: 4.335

2.  Interactions of grapefruit juice and cardiovascular medications: A potential risk of toxicity.

Authors:  Gareth E Lim; Timao Li; Harpal S Buttar
Journal:  Exp Clin Cardiol       Date:  2003

Review 3.  Pharmacokinetics of haloperidol: an update.

Authors:  S Kudo; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

Review 4.  Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.

Authors:  G K Dresser; J D Spence; D G Bailey
Journal:  Clin Pharmacokinet       Date:  2000-01       Impact factor: 6.447

Review 5.  The effect of grapefruit juice on drug disposition.

Authors:  Michael J Hanley; Paul Cancalon; Wilbur W Widmer; David J Greenblatt
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-01-22       Impact factor: 4.481

Review 6.  Effects of food on clinical pharmacokinetics.

Authors:  B N Singh
Journal:  Clin Pharmacokinet       Date:  1999-09       Impact factor: 6.447

7.  Effects of grapefruit juice and orange juice on the intestinal efflux of P-glycoprotein substrates.

Authors:  Run Tian; Noriko Koyabu; Hitomi Takanaga; Hirotami Matsuo; Hisakazu Ohtani; Yasufumi Sawada
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.